1[1]Hemandez - presa MA, Martin - Ventura JL, Ortego M, et al. Atorvastatin reduces the expression of cyclooxgenase- 2 in a rabbit model of atherosclerosis and in cultured vascular smooth muscle cells [J].Atherosclerosis, 2002,160(1) :49 - 58.
2[2]Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis[J].Circulation, 2002,105(9): 1135 - 1143.
4[4]Pasceri V, Willerson JT, Yeh ET. Direct proinflammatory effect of Creactive protein on human endothelial cells[J]. Circulation, 2000, 102(18) :2165 - 2168.
5[5]Baetta R, Camera M, Comparato C, et al. Fluvastatin reduces tissue factor expression and macrophage accumulation in carotid lesions of cholesterol - fed rabbits in the absence of lipid lowering[J]. Arterioscler Thromb Vasc Biol, 2002, 22(4):692- 698.
6[6]Aikawa M, Rabkin E, Sugiyama S, et al. An HMG- CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro [J] .Circulation, 2001,103(2) :276 - 283.
7[7]Grisby M, Nordin- Fredriksson G, Shah PK, et al. Pravastatin treatment increases collagen content and decreases lipid content, inflammation,metalloproteinascs, and cell death in human carotid plaques: implications for plaque stabilization[J]. Circulation, 2001,103(7): 926-933.
8[8]Sposito AC, Chapman MJ. Statin therapy in acute coronary syndromes:mechanistic insight into clinical benefit [ J ] . Arterioscler Thromb Vasc Biol, 2002, 22(10):1524- 1534.
9[9]Ridker PM, Rifai N, Clearfield M, et al. Measurement of.C - reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events[J]. N Engl J Med, 2001, 344(26):1959- 1965.
10[10]Kinlay S, Timms T, Clark M, et al. Comparison of effect of intensive lipid lowering with atorvastatin to less intensive lowering with lovastatin on C - reactive protein in patients with stable angina pectoris and inducible myocardial ischemia[J]. Am J Cardiol,2002,89(10): 1205 -1207.
